A‐kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C‐X‐C motif) ligand 1/chemokine (C‐X‐C motif) ligand 2 in acute myeloid leukemia

Abstract

Background This study aimed to explore the association of A‐kinase interacting protein 1 (AKIP1) with chemokine (C‐X‐C motif) ligand (CXCL) 1/CXCL2, and further investigate their correlation with clinical features and prognosis in acute myeloid leukemia (AML) patients. Methods Totally 160 de novo AML patients were recruited, and their bone marrow samples were collected before treatment for detecting the expressions of AKIP1, CXCL1, and CXCL2 by the quantitative polymerase chain reaction. Complete remission (CR) was assessed after induction treatment, and event‐free survival (EFS) and overall survival (OS) were calculated. Results AKIP1 expression was positively associated with CXCL1 (P < .001) and CXCL2 expression (P < .001). AKIP1 high expression was correlated with FAB classification (P = .022), monosomal karyotype (P = .001), and poor risk stratification (P = .013), while CXCL2 high expression was associated with monosomal karyotype (P = .001). As for treatment response, AKIP1 high expression exhibited a trend to be increased in non‐CR patients compared with CR patients, while without statistical significance (P = .105). However, no correlation of CXCL1 (P = .418) or CXCL2 (P = .685) with CR achievement was observed. Most importantly, AKIP1 and CXCL1 were negatively correlated with accumulating EFS and OS (all P < .05), while CXCL2 only showed a trend to be negatively associated with accumulating EFS (P = .069) and OS (P = .055; but without statistical significance). Conclusion AKIP1 might serve as a novel biomarker for worse AML prognosis through the interaction of CXCL1/CXCL2.

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

“…Hao et al. investigated the relationship between CXCL1/CXCL2, clinical characteristics, and prognosis in patients with AML ( 36 ). Expression of CXCL1 and CXCL2 was detected using quantitative-PCR in bone marrow samples from 160 patients with de novo AML.…”

Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma

“…It was observed that AKIP1 protein and mRNA expressions were upregulated in patients with MM compared to healthy donors, which was consistent with the previous findings that AKIP1 was upregulated in patients with AML compared to healthy controls. 12 The ROC curve analysis further presented good value of AKIP1 in differentiating patients with MM from healthy donors. The possible reasons might include that according to the previous study, activation of NF-κB signaling pathway is associated with several diverse genetic abnormalities, including cytogenetic abnormalities and chromosomal translocation, which lead to the initiation and progression of malignant MM events.…”

“… 7 , 8 As a key regulator of NF-κB signaling, AKIP1 is implicated in various aspects of physiological and biological activities (such as immunoinflammatory responses, cell metabolism), which serve as an oncogenic factor in pathogenesis of leukemia and solid cancers. 9 - 13 Functionally, AKIP1 promotes tumor angiogenesis and lymphangiogenesis via activating downstream oncogenes expression of NF-κB signaling in several solid tumors. 11 , 14 , 15 Regarding the role of AKIP1 in hematological malignancies, clinically, AKIP1 is associated with poor risk stratification and worse prognosis in patients with acute myeloid leukemia (AML).…”

“… 11 , 14 , 15 Regarding the role of AKIP1 in hematological malignancies, clinically, AKIP1 is associated with poor risk stratification and worse prognosis in patients with acute myeloid leukemia (AML). 12 In addition, several studies disclose that activation of NF-κB signaling, which is regulated by AKIP1, is a key factor for the growth and survival of MM cells. 16 , 17 Furthermore, we performed a preliminary research with a small sample size population and observed that AKIP1 was upregulated in patients with MM compared to healthy donors.…”

A‐kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients

“…Interesting, its tumor expression was positively associated with tumor size, extrathyroidal invasion, pT stage, and pN stage in PTC patients. The probable explanations were as follows: (a) AKIP1 might activate multiple oncogenic signaling pathways (including Wnt/β‐catenin signaling) to promoting the tumorigenicity of PTC; hence, tumor tissue of PTC was characterized by increased AKIP1 expression compared to adjacent tissue 18 . (b) Upregulated ARIP1 (as its role in gastric cancer) could induce Slug‐induced EMT to promote cell proliferation, cell invasion and cell migration to facilitate tumor growth and metastasis, which further accelerated tumor progression and extrathyroidal invasion in PTC patients 15 .…”